Neeße, Albrecht

[["dc.bibliographiccitation.firstpage","161"],["dc.bibliographiccitation.journal","EBioMedicine"],["dc.bibliographiccitation.lastpage","168"],["dc.bibliographiccitation.volume","48"],["dc.contributor.author","Ramu, Iswarya"],["dc.contributor.author","Buchholz, Sören M."],["dc.contributor.author","Patzak, Melanie S."],["dc.contributor.author","Goetze, Robert G."],["dc.contributor.author","Singh, Shiv K."],["dc.contributor.author","Richards, Frances M."],["dc.contributor.author","Jodrell, Duncan I."],["dc.contributor.author","Sipos, Bence"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Hessmann, Elisabeth"],["dc.contributor.author","Neesse, Albrecht"],["dc.date.accessioned","2020-12-10T14:23:31Z"],["dc.date.available","2020-12-10T14:23:31Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.ebiom.2019.09.024"],["dc.identifier.issn","2352-3964"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16852"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71949"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1978"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Buchholz, Soeren M."],["dc.contributor.author","Goetze, Robert G."],["dc.contributor.author","Singh, Shiv K."],["dc.contributor.author","Ammer-Herrmenau, Christoph"],["dc.contributor.author","Richards, Frances M."],["dc.contributor.author","Jodrell, Duncan I."],["dc.contributor.author","Buchholz, Malte"],["dc.contributor.author","Michl, Patrick"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Hessmann, Elisabeth"],["dc.contributor.author","Neesse, Albrecht"],["dc.date.accessioned","2021-04-14T08:25:07Z"],["dc.date.available","2021-04-14T08:25:07Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/cancers12071978"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17498"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81527"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2072-6694"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","175"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Digestion"],["dc.bibliographiccitation.lastpage","184"],["dc.bibliographiccitation.volume","92"],["dc.contributor.author","Schober, Marvin"],["dc.contributor.author","Javed, Muhammad A."],["dc.contributor.author","Beyer, Georg"],["dc.contributor.author","Le, Nha"],["dc.contributor.author","Vinci, Alessio"],["dc.contributor.author","Sund, Malin"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Krug, Sebastian"],["dc.date.accessioned","2018-11-07T10:02:53Z"],["dc.date.available","2018-11-07T10:02:53Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Pancreatic ductal adenocarcinoma (PDAC) is characterised by an extremely poor overall survival (OS) compared to other solid tumours. As the incidence of the disease is rising and the treatment options are limited, PDAC is projected to be the 2nd leading cause of cancer-related deaths in the United States by 2030. A majority of patients are not eligible for curative resection at the time of diagnosis, and those that are resected will often relapse within the first few years after surgery. Summary: Until recently, the nucleoside analogue gemcitabine has been the standard of care for patients with non-resectable PDAC with only marginal effects on OS. In 2011, the gemcitabine-free FOLFIRINOX regimen (folinic acid, fluorouracil, irinotecan and oxaliplatin) showed a significant survival advantage for patients with metastatic PDAC in a phase III trial. In 2013, the Metastatic Pancreatic Adenocarcinoma Trial phase III trial with nano-formulated albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine also resulted in a significant survival extension compared to gemcitabine monotherapy. However, both intensified therapy regimens show a broad spectrum of side effects and patients need to be carefully selected for the most appropriate protocol. Key Message: In this study, recent advances in the chemotherapeutic options available to treat metastatic PDAC and their implications for today's treatment choices are reviewed. (C) 2015 S. Karger AG, Basel"],["dc.description.sponsorship","European Pancreas Club; United European Gastroenterologists; Celgene"],["dc.identifier.doi","10.1159/000439523"],["dc.identifier.isi","000362928900009"],["dc.identifier.pmid","26372949"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38324"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1421-9867"],["dc.relation.issn","0012-2823"],["dc.title","New Advances in the Treatment of Metastatic Pancreatic Cancer"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Krug, Sebastian"],["dc.contributor.author","Beyer, Georg"],["dc.contributor.author","Javed, Muhammad A."],["dc.contributor.author","Le, N."],["dc.contributor.author","Vinci, Alessio"],["dc.contributor.author","Morgan, R. D."],["dc.contributor.author","Hubner, R."],["dc.contributor.author","Valle, J. W."],["dc.contributor.author","Wong, Hubert"],["dc.contributor.author","Chowdhury, S."],["dc.contributor.author","Ma, Y. Ting"],["dc.contributor.author","Palmer, D."],["dc.contributor.author","Maisonneuve, P."],["dc.contributor.author","Neesse, A."],["dc.contributor.author","Sund, Malin"],["dc.contributor.author","Schober, Marvin"],["dc.date.accessioned","2018-11-07T10:07:19Z"],["dc.date.available","2018-11-07T10:07:19Z"],["dc.date.issued","2016"],["dc.description.sponsorship","Pancreas2000"],["dc.identifier.doi","10.1093/annonc/mdw371.68"],["dc.identifier.isi","000393912500682"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39251"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","41st Congress of the European-Society-for-Medical-Oncology (ESMO)"],["dc.relation.eventlocation","Copenhagen, DENMARK"],["dc.relation.issn","1569-8041"],["dc.relation.issn","0923-7534"],["dc.title","Intensified chemotherapy for metastatic pancreatic cancer: interim analysis of a large retrospective pan-European database and real life evaluation"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","878"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","United European Gastroenterology Journal"],["dc.bibliographiccitation.lastpage","885"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Ammer‐Herrmenau, Christoph"],["dc.contributor.author","Pfisterer, Nina"],["dc.contributor.author","Weingarten, Mark FJ"],["dc.contributor.author","Neesse, Albrecht"],["dc.date.accessioned","2021-04-14T08:23:59Z"],["dc.date.available","2021-04-14T08:23:59Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1177/2050640620944720"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81119"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","2050-6414"],["dc.relation.issn","2050-6406"],["dc.title","The microbiome in pancreatic diseases: Recent advances and future perspectives"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2561"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Gut"],["dc.bibliographiccitation.lastpage","2573"],["dc.bibliographiccitation.volume","71"],["dc.contributor.affiliation","Latif, Muhammad Umair; \r\n1\r\nDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Schmidt, Geske Elisabeth; \r\n1\r\nDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Mercan, Sercan; \r\n1\r\nDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Rahman, Raza; \r\n2\r\nGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"],["dc.contributor.affiliation","Gibhardt, Christine Silvia; \r\n3\r\nMolecular Physiology, Institute of Cardiovascular Physiology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Stejerean-Todoran, Ioana; \r\n3\r\nMolecular Physiology, Institute of Cardiovascular Physiology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Reutlinger, Kristina; \r\n1\r\nDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Hessmann, Elisabeth; \r\n1\r\nDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Singh, Shiv K; \r\n1\r\nDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Moeed, Abdul; \r\n4\r\nInstitute for Microbiology and Hygiene, Medical Center-University of Freiburg, Freiburg, Baden-Württemberg, Germany"],["dc.contributor.affiliation","Rehman, Abdul; \r\n5\r\nInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Butt, Umer Javed; \r\n6\r\nClinical Neuroscience, Max-Planck-Institute for Experimental Medicine, Goettingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Bohnenberger, Hanibal; \r\n7\r\nInstitute of Pathology, University Medical Center Göttingen, Gottingen, Germany"],["dc.contributor.affiliation","Stroebel, Philipp; \r\n7\r\nInstitute of Pathology, University Medical Center Göttingen, Gottingen, Germany"],["dc.contributor.affiliation","Bremer, Sebastian Christopher; \r\n1\r\nDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Neesse, Albrecht; \r\n1\r\nDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Bogeski, Ivan; \r\n3\r\nMolecular Physiology, Institute of Cardiovascular Physiology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.affiliation","Ellenrieder, Volker; \r\n1\r\nDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany"],["dc.contributor.author","Latif, Muhammad Umair"],["dc.contributor.author","Schmidt, Geske Elisabeth"],["dc.contributor.author","Mercan, Sercan"],["dc.contributor.author","Rahman, Raza"],["dc.contributor.author","Gibhardt, Christine Silvia"],["dc.contributor.author","Stejerean-Todoran, Ioana"],["dc.contributor.author","Reutlinger, Kristina"],["dc.contributor.author","Hessmann, Elisabeth"],["dc.contributor.author","Singh, Shiv K."],["dc.contributor.author","Moeed, Abdul"],["dc.contributor.author","Rehman, Abdul"],["dc.contributor.author","Butt, Umer Javed"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Bremer, Sebastian Christopher"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Bogeski, Ivan"],["dc.contributor.author","Ellenrieder, Volker"],["dc.date.accessioned","2022-12-07T08:25:00Z"],["dc.date.available","2022-12-07T08:25:00Z"],["dc.date.issued","2022-04-01"],["dc.date.updated","2022-12-07T00:46:04Z"],["dc.description.abstract","ObjectivesNon-alcoholic fatty liver disease (NAFLD) can persist in the stage of simple hepatic steatosis or progress to steatohepatitis (NASH) with an increased risk for cirrhosis and cancer. We examined the mechanisms controlling the progression to severe NASH in order to develop future treatment strategies for this disease.DesignNFATc1 activation and regulation was examined in livers from patients with NAFLD, cultured and primary hepatocytes and in transgenic mice with differential hepatocyte-specific expression of the transcription factor (Alb-cre, NFATc1c.a\r\n. and NFATc1Δ/Δ\r\n). Animals were fed with high-fat western diet (WD) alone or in combination with tauroursodeoxycholic acid (TUDCA), a candidate drug for NAFLD treatment. NFATc1-dependent ER stress-responses, NLRP3 inflammasome activation and disease progression were assessed both in vitro and in vivo.ResultsNFATc1 expression was weak in healthy livers but strongly induced in advanced NAFLD stages, where it correlates with liver enzyme values as well as hepatic inflammation and fibrosis. Moreover, high-fat WD increased NFATc1 expression, nuclear localisation and activation to promote NAFLD progression, whereas hepatocyte-specific depletion of the transcription factor can prevent mice from disease acceleration. Mechanistically, NFATc1 drives liver cell damage and inflammation through ER stress sensing and activation of the PERK-CHOP unfolded protein response (UPR). Finally, NFATc1-induced disease progression towards NASH can be blocked by TUDCA administration.ConclusionNFATc1 stimulates NAFLD progression through chronic ER stress sensing and subsequent activation of terminal UPR signalling in hepatocytes. Interfering with ER stress-responses, for example, by TUDCA, protects fatty livers from progression towards manifest NASH."],["dc.description.sponsorship","the Volkswagen-Stiftung"],["dc.description.sponsorship","http://dx.doi.org/10.13039/501100001659Deutsche Forschungsgemeinschaft"],["dc.description.sponsorship","German Cancer Aid"],["dc.identifier","35365570"],["dc.identifier.doi","10.1136/gutjnl-2021-325013"],["dc.identifier.pmid","35365570"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118455"],["dc.identifier.url","https://sfb1190.med.uni-goettingen.de/production/literature/publications/173"],["dc.language.iso","en"],["dc.publisher","BMJ Publishing Group Ltd and British Society of Gastroenterology"],["dc.relation","SFB 1190: Transportmaschinen und Kontaktstellen zellulärer Kompartimente"],["dc.relation","SFB 1190 | P17: Die Rolle mitochondrialer Kontaktstellen im Rahmen tumorrelevanter Calcium- und Redox-Signalwege"],["dc.relation.eissn","1468-3288"],["dc.relation.issn","0017-5749"],["dc.relation.workinggroup","RG Bogeski"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","http://creativecommons.org/licenses/by-nc/4.0/"],["dc.title","NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1559"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","European Journal of Gastroenterology & Hepatology"],["dc.bibliographiccitation.lastpage","1565"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Bremer, Sebastian C.B."],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Neesse, Albrecht"],["dc.date.accessioned","2021-04-14T08:24:50Z"],["dc.date.available","2021-04-14T08:24:50Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1097/MEG.0000000000001675"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81439"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0954-691X"],["dc.title","Noninvasive assessment of liver fibrosis in a real-world cohort of patients with known or suspected chronic liver disease using 2D-shear wave elastography"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","342"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","342"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Corrie, Philippa"],["dc.contributor.author","Qian, Wendi"],["dc.contributor.author","Basu, Bristi"],["dc.contributor.author","Jodrell, Duncan Ian"],["dc.contributor.author","Falk, Stephen"],["dc.contributor.author","Iwuji, Chinenyu"],["dc.contributor.author","Wasan, Harpreet"],["dc.contributor.author","Palmer, Daniel H."],["dc.contributor.author","Scott-Brown, Martin"],["dc.contributor.author","Wadsley, Jonathan"],["dc.contributor.author","Arif, Seema Safia"],["dc.contributor.author","Babaoglan, A. Burcu"],["dc.contributor.author","Dalchau, Katy Marie"],["dc.contributor.author","Gopinathan, Aarthi"],["dc.contributor.author","Chhabra, Anita"],["dc.contributor.author","Machin, Andrea"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Tuveson, David A."],["dc.contributor.author","Valle, Juan W."],["dc.date.accessioned","2020-12-10T18:41:34Z"],["dc.date.available","2020-12-10T18:41:34Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1200/JCO.2017.35.4_suppl.342"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77616"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC)."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2622"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Leukemia & Lymphoma"],["dc.bibliographiccitation.lastpage","2627"],["dc.bibliographiccitation.volume","59"],["dc.contributor.author","Peil-Grun, Anke"],["dc.contributor.author","Trenker, Corinna"],["dc.contributor.author","Görg, Konrad"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Haasenritter, Jörg"],["dc.contributor.author","Görg, Christian"],["dc.date.accessioned","2020-12-10T18:14:59Z"],["dc.date.available","2020-12-10T18:14:59Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1080/10428194.2018.1439170"],["dc.identifier.eissn","1029-2403"],["dc.identifier.issn","1042-8194"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74692"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Diagnostic accuracy and interobserver agreement of contrast-enhanced ultrasound in the evaluation of residual lesions after treatment for malignant lymphoma and testicular cancer: a retrospective pilot study in 52 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","ueg2.12262"],["dc.bibliographiccitation.journal","United European Gastroenterology Journal"],["dc.contributor.author","Ammer‐Herrmenau, Christoph"],["dc.contributor.author","Wolf, Laurin"],["dc.contributor.author","Nasrin, Syeda S."],["dc.contributor.author","Ramu, Iswarya"],["dc.contributor.author","Roggiolani, Roberta"],["dc.contributor.author","Goetze, Robert G."],["dc.contributor.author","Buchholz, Soeren M."],["dc.contributor.author","Sendler, Mathias"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.date.accessioned","2022-07-01T07:35:08Z"],["dc.date.available","2022-07-01T07:35:08Z"],["dc.date.issued","2022"],["dc.description.abstract","Background:Acute pancreatitis(AP) is a frequent cause for hospitalization.How-ever, moleculardeterminantsthat modulateseverity of experimentalpancreatitisareonlypartiallyunderstood.Objective:To investigatethe role of secreted protein acidic and rich in cysteine(SPARC)duringcerulein‐inducedAPinmice.Methods:APwasinducedbyrepeatedceruleininjectionsinSPARCknock‐outmice(SPARC−/−)andcontrollittermates(SPARC+/+).Secretedproteinacidicandrichincysteine expressionand severity of AP were determinedby histopathologicalscoring, immunohistochemistry,and biochemicalassays. For functionalanalysis,primary murine acinar cell cultures with subsequentamylase release assays wereemployed.Proteomeprofiler assay and ELISA were conductedfrom pancreatictissuelysates,andco‐immunofluorescencewasperformed.Results:Upon cerulein induction,SPARC expressionwas robustly induced inpancreaticstellate cells (PSCs) but not in acinar cells. Genetic SPARC ablationresultedinattenuatedseverityofAPwithsignificantlyreducedlevelsofpancreaticnecrosis, apoptosis,immune cell infiltration,and reduced fibrosis upon chronicstimulation.However,the release of amylase upon cerulein stimulationin primaryacinar cell culture from SPARC+/+and SPARC−/−was indistinguishable.Notably,immunecellderivedC‐C MotifChemokineLigand2(CCL2)washighlyelevatedinSPARC+/+pancreatictissue potentiallylinking PSC derived SPARC with CCL2 in-ductioninAP.Conclusion:SPARCmediatestheseverityofAP.ThepotentiallinkbetweenSPARCandtheCCL2axiscouldopennewavenuesfortailoredtherapeuticinterventionsinAPpatientsandwarrantsfurtherinvestigations."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1002/ueg2.12262"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112096"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-581"],["dc.relation.eissn","2050-6414"],["dc.relation.issn","2050-6406"],["dc.rights","CC BY-NC-ND 4.0"],["dc.title","Activity of acute pancreatitis is modified by secreted protein acidic and rich in cysteine ablation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]